T. Rowe Price Associates
ORGO icon

T. Rowe Price Associates’s Organogenesis Holdings ORGO Stock Holding History

T. Rowe Price Associates’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Buy
54,876
+12,724
+30% +$31.1K ﹤0.01% 3104
2026
Q1 		$100K Buy
42,152
+1,874
+5% +$6.49K ﹤0.01% 3004
2025
Q4 		$209K Buy
40,278
+3,825
+10% +$18.5K ﹤0.01% 2793
2025
Q3 		$154K Buy
36,453
+3,564
+11% +$16.6K ﹤0.01% 2842
2025
Q2 		$121K Buy
32,889
+3,997
+14% +$14.9K ﹤0.01% 2860
2025
Q1 		$125K Sell
28,892
-7
-0% -$28 ﹤0.01% 2776
2024
Q4 		$93K Sell
28,899
-24,540
-46% -$82.3K ﹤0.01% 2844
2024
Q3 		$153K Buy
53,439
+2,488
+5% +$6.98K ﹤0.01% 2741
2024
Q2 		$143K Hold
50,951
– – ﹤0.01% 2680
2024
Q1 		$145K Buy
50,951
+5,359
+12% +$18.2K ﹤0.01% 2702
2023
Q4 		$187K Buy
45,592
+921
+2% +$2.58K ﹤0.01% 2566
2023
Q3 		$143K Buy
44,671
+785
+2% +$2.49K ﹤0.01% 2589
2023
Q2 		$146K Sell
43,886
-5,480
-11% -$16.2K ﹤0.01% 2612
2023
Q1 		$106K Buy
49,366
+1,891
+4% +$4.67K ﹤0.01% 2676
2022
Q4 		$128K Buy
47,475
+15,602
+49% +$45.5K ﹤0.01% 2664
2022
Q3 		$104K Buy
31,873
+5,052
+19% +$22.8K ﹤0.01% 2715
2022
Q2 		$131K Buy
26,821
+300
+1% +$1.85K ﹤0.01% 2700
2022
Q1 		$202K Buy
26,521
+15,957
+151% +$124K ﹤0.01% 2710
2021
Q4 		$98K Sell
10,564
-800
-7% -$8.5K ﹤0.01% 2880
2021
Q3 		$162K Hold
11,364
– – ﹤0.01% 2766
2021
Q2 		$189K Buy
+11,364
New +$212K ﹤0.01% 2741

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

T. Rowe Price Associates's ORGO Position: Q2 2026 in Review

T. Rowe Price Associates increased its Organogenesis Holdings (ORGO) stake by 30% in Q2 2026, buying an estimated $31.1K and bringing the position to 54,876 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #3104.

T. Rowe Price Associates first reported a position in ORGO in Q2 2021 and has held it in 21 quarters since. The position peaked at $209K in Q4 2025. 135 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

  • T. Rowe Price Associates held 54,876 shares of Organogenesis Holdings worth $134K as of Q2 2026.
  • T. Rowe Price Associates bought 12,724 Organogenesis Holdings shares in Q2 2026, an estimated $31.1K.
  • Organogenesis Holdings made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3104 holding.
  • T. Rowe Price Associates first reported a position in Organogenesis Holdings in Q2 2021 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Organogenesis Holdings position peaked at $209K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.